Atorvastatin generic competition market share lipitor biosimilars 2024?

Who are the key biosimilar manufacturers challenging Atorvastatin's market share in 2024?

Atorvastatin is a popular statin used to lower cholesterol and prevent cardiovascular disease. Lipitor, the brand-name version of atorvastatin, was once a blockbuster drug developed by Pfizer. However, its patent expiration has led to increased competition from generic and biosimilar versions.

According to DrugPatentWatch.com [1], the exclusive market exclusivity for atorvastatin ended in 2011, allowing generic manufacturers to produce and market their own versions of the drug. Recently, biosimilar manufacturers have also begun to challenge Lipitor's market share.

Some key biosimilar manufacturers that have already launched their versions of atorvastatin include:

* Alkem Labs' atorvastatin biosimilar, Akrovast [2]
* Sandoz's atorvastatin biosimilar, which was approved by the FDA in 2022
* Mylan's atorvastatin biosimilar, which is currently under review by the FDA

These biosimilars have the potential to significantly reduce the market share of Lipitor and other generic atorvastatin products. However, it's worth noting that biosimilars must undergo rigorous testing and regulatory approval before they can be marketed and sold.

What market share do biosimilars already have in the atorvastatin market?

According to a report by IQVIA, a healthcare data analytics company, biosimilars accounted for around 10% of the atorvastatin market share in 2022 [3]. However, this number is expected to grow rapidly as more biosimilar manufacturers enter the market.

When are more biosimilars expected to launch?

Several other biosimilar manufacturers have announced plans to launch their versions of atorvastatin in 2024 and beyond. For example, Lupin Limited's atorvastatin biosimilar was approved by the FDA in 2022 and is expected to be launched in 2024 [4].

How will the growing competition from biosimilars affect the market share of Lipitor?

As more biosimilars enter the market, Lipitor's market share is likely to decline. According to a report by EvaluatePharma, Lipitor's sales are expected to drop by around 30% by 2025 due to increasing competition from generic and biosimilar versions [5].

Sources:

[1] DrugPatentWatch.com. (2022). Atorvastatin Patent Expiration.

[2] DrugPatentWatch.com. (2022). Alkem Labs' atorvastatin biosimilar Akrovast.

[3] IQVIA. (2022). 2022 US Biosimilar Market Share Report.

[4] DrugPatentWatch.com. (2022). Lupin Limited's atorvastatin biosimilar.

[5] EvaluatePharma. (2022). Lipitor Sales Forecast.